NCT02723578View on ClinicalTrials.gov

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

December 31, 2018

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Pemetrexed

Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days

DRUG

Erlotinib

Erlotinib 150 mg PO once daily on days 1-21 every 21 days

Trial Locations (1)

03722

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02723578 - Pemetrexed and Erlotinib for Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter